About Splicing factor 3A subunit 2
Splicing factor 3A subunit 2 (SF3A2) is a protein
from Homo sapiens identified by UniProt accession
Q15428, 464 residues long.
MolForge cross-references it against 0 known binders and
37 disease associations.
Target properties
| Protein name | Splicing factor 3A subunit 2 |
| UniProt accession | Q15428 |
| Gene | SF3A2 |
| Organism | Homo sapiens |
| Length | 464 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (37)
Diseases linked to this target (Open Targets).
- body mass index · score 0.19
- neurodegenerative disease · score 0.17
- mean corpuscular volume · score 0.15
- body height · score 0.12
- pulse pressure measurement · score 0.09
- migraine disorder · score 0.08
- triple-negative breast cancer · score 0.07
- systolic blood pressure · score 0.07
- body fat percentage · score 0.04
- eosinophil count · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15428-F1 | alphafold | PREDICTED | 64.05 | — |
Amino-acid sequence (464 residues)
MDFQHRPGGK TGSGGVASSS ESNRDRRERL RQLALETIDI NKDPYFMKNH LGSYECKLCL TLHNNEGSYL AHTQGKKHQT NLARRAAKEA KEAPAQPAPE KVKVEVKKFV KIGRPGYKVT KQRDSEMGQQ SLLFQIDYPE IAEGIMPRHR FMSAYEQRIE PPDRRWQYLL MAAEPYETIA FKVPSREIDK AEGKFWTHWN RETKQFFLQF HFKMEKPPAP PSLPAGPPGV KRPPPPLMNG LPPRPPLPES LPPPPPGGLP LPPMPPTGPA PSGPPGPPQL PPPAPGVHPP APVVHPPASG VHPPAPGVHP PAPGVHPPAP GVHPPTSGVH PPAPGVHPPA PGVHPPAPGV HPPAPGVHPP APGVHPPPSA GVHPQAPGVH PAAPAVHPQA PGVHPPAPGM HPQAPGVHPQ PPGVHPSAPG VHPQPPGVHP SNPGVHPPTP MPPMLRPPLP SEGPGNIPPP PPTN
Explore Splicing factor 3A subunit 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets